We are pleased to announce that CURLIM will be participating in the BIO International Convention 2026, taking place in San Diego from June 22-25, 2026, as part of the French Pavilion and the Business France Booster Program. Bringing together…
We’re pleased to announce that Laurent Richebourg, CEO of CURLIM will be participating in BioEquity Europe 2026 and presenting CURLIM , in Prague from May 4–6. BioEquity is one of Europe’s leading investor conferences, bringing together biotech companies, investors, and…
On March 28, CURLIM took part in the CMT France 2026 Congress, held at the University of Medicine in Lille and dedicated to the theme: “Living with CMT: towards better well-being.” The event brought together over 200 participants : patients,…
This March, CURLIM will be in Lisbon for Spring Innovation Week, bringing together two of Europe’s most influential life sciences events: 📍 BIO-Europe Spring | March 23–25, 2026📍 LSX World Congress Europe | March 25–26, 2026 During these two events,…
We are pleased to announce our participation in the 1st Annual European Neuroscience Innovation Forum, taking place in Zurich from March 3 to 5, 2026. During the event, we will be pitching CLM001, our breakthrough nanodrug targeting the root causes…
🌟We’re getting ready for BioFIT 2025 ! We’re delighted to announce CURLIM’s participation in BioFIT 2025, taking place in Strasbourg on December 2–3. And we are also proud to share that we have been selected to pitch in the “Rare…
A new week, and another major achievement for CURLIM ! A few weeks ago, we announced our Orphan Drug Designation in Europe, and today, we’re proud to share that CURLIM has also obtained Orphan Drug Designation in the United States.…
We’re excited to announce that CURLIM will be attending BIO-Europe in Vienna — November 3–5, 2025! Following our recent Orphan Drug Designation (EU) and our recognition by the French government for innovative research (I-Lab award-winning project), we are proud to…
We are proud to announce that CURLIM has been awarded as part of the 2024–2025 State Innovation Challenge, joining 147 projects supported by the French government under #France2030. This recognition marks a major milestone for CURLIM It reflects our determination…
We are pleased to announce that the European Commission, following a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted CLM001 orphan drug designation for the treatment of Charcot-Marie-Tooth disease (CMT).…